Search

Your search keyword '"Toyama, Takanori"' showing total 8 results
Start Over Author "Toyama, Takanori" Search Limiters Available in Library Collection
8 results on '"Toyama, Takanori"'

1. Integrated genetic and clinical prognostic factors for aggressive adult T-cell leukemia/lymphoma

Author

Kameda, Takuro, primary, Kataoka, Keisuke, additional, Kamiunten, Ayako, additional, Hidaka, Michihiro, additional, Miyoshi, Hiroaki, additional, Nakano, Nobuaki, additional, Nosaka, Kisato, additional, Yoshimitsu, Makoto, additional, Yasunaga, Jun-ichirou, additional, Kogure, Yasunori, additional, Shide, Kotaro, additional, Miyahara, Masaharu, additional, Sakamoto, Takashi, additional, Akizuki, Keiichi, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Koya, Junji, additional, Kawano, Noriaki, additional, Yamashita, Kiyoshi, additional, Kawano, Hiroshi, additional, Toyama, Takanori, additional, Maeda, Kouichi, additional, Marutsuka, Kosuke, additional, Imaizumi, Yoshitaka, additional, Kato, Koji, additional, Sugio, Takeshi, additional, Tokunaga, Masahito, additional, Tashiro, Yukie, additional, Takaori-Kondo, Akifumi, additional, Miyazaki, Yasushi, additional, Akashi, Koichi, additional, Ishitsuka, Kenji, additional, Matsuoka, Masao, additional, Ohshima, Koichi, additional, Watanabe, Toshiki, additional, Kitanaka, Akira, additional, Utsunomiya, Atae, additional, Ogawa, Seishi, additional, and Shimoda, Kazuya, additional

Published
2023
Full Text
View/download PDF

2. Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma

Author

Kameda, Takuro, primary, Shide, Kotaro, additional, Tahira, Yuki, additional, Sekine, Masaaki, additional, Sato, Seiichi, additional, Ishizaki, Junzo, additional, Takeuchi, Masanori, additional, Akizuki, Keiichi, additional, Kamiunten, Ayako, additional, Shimoda, Haruko, additional, Toyama, Takanori, additional, Maeda, Kouichi, additional, Yamashita, Kiyoshi, additional, Kawano, Noriaki, additional, Kawano, Hiroshi, additional, Hidaka, Tomonori, additional, Yamaguchi, Hideki, additional, Kubuki, Yoko, additional, Kitanaka, Akira, additional, Matsuoka, Hitoshi, additional, and Shimoda, Kazuya, additional

Published
2022
Full Text
View/download PDF

4. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan

Author

Akizuki, Keiichi, primary, Matsuoka, Hitoshi, additional, Toyama, Takanori, additional, Kamiunten, Ayako, additional, Sekine, Masaaki, additional, Shide, Kotaro, additional, Kameda, Takuro, additional, Kawano, Noriaki, additional, Maeda, Kouichi, additional, Takeuchi, Masanori, additional, Kawano, Hiroshi, additional, Sato, Seiichi, additional, Ishizaki, Junzo, additional, Tahira, Yuki, additional, Shimoda, Haruko, additional, Hidaka, Tomonori, additional, Yamashita, Kiyoshi, additional, Kubuki, Yoko, additional, and Shimoda, Kazuya, additional

Published
2020
Full Text
View/download PDF

6. Mogamulizumab for ATLL in Clinical Practice

Author

Sekine, Masaaki, primary, Takeuchi, Masaki, additional, Toyama, Takanori, additional, Maeda, Kouichi, additional, Sato, Seiichi, additional, Yamashita, Kiyoshi, additional, Ishizaki, Junzo, additional, Keiichi, Akizuki, additional, Kamiunten, Ayako, additional, Kameda, Takuro, additional, Shide, Kotaro, additional, Hidaka, Tomonori, additional, Kubuki, Yoko, additional, Kitanaka, Akira, additional, and Shimoda, Kazuya, additional

Published
2016
Full Text
View/download PDF

7. Prognostic Factor, Including Relative Dose Intensity, For Adult T-Cell Leukemia/Lymphoma In Clinical Practice

Author

Kamiunten, Ayako, primary, Kitanaka, Akira, additional, Kubuki, Yoko, additional, Hidaka, Tomonori, additional, Shide, Kotaro, additional, Kameda, Takuro, additional, Sekine, Masaaki, additional, Yamashita, Kiyoshi, additional, Matsuoka, Hitoshi, additional, Kawano, Hiroshi, additional, Toyama, Takanori, additional, Satou, Seiichi, additional, Maeda, Kouichi, additional, Ishizaki, Junzo, additional, and Shimoda, Kazuya, additional

Published
2013
Full Text
View/download PDF

8. Real-World Data on Clinical Features, Outcomes, and Prognostic Factors in Multiple Myeloma from Miyazaki Prefecture, Japan.

Author

Akizuki, Keiichi, Matsuoka, Hitoshi, Toyama, Takanori, Kamiunten, Ayako, Sekine, Masaaki, Shide, Kotaro, Kameda, Takuro, Kawano, Noriaki, Maeda, Kouichi, Takeuchi, Masanori, Kawano, Hiroshi, Sato, Seiichi, Ishizaki, Junzo, Tahira, Yuki, Shimoda, Haruko, Hidaka, Tomonori, Yamashita, Kiyoshi, Kubuki, Yoko, and Shimoda, Kazuya

Subjects
MULTIPLE myeloma, PROGNOSIS, STEM cell transplantation, DIAGNOSIS, MULTIVARIATE analysis, PLASMACYTOMA
Abstract

The prognosis of multiple myeloma (MM) has improved with the introduction of novel agents. These data are largely derived from clinical trials and might not reflect real-world patient outcomes accurately. We surveyed real-world data from 284 patients newly diagnosed with MM between 2010 and 2018 in Miyazaki Prefecture. The median follow-up period was 32.8 months. The median age at diagnosis was 71 years, with 68% of patients aged >65 years. The International Staging System (ISS) stage at diagnosis was I in 18.4% of patients, II in 34.1%, and III in 47.5%. Bortezomib-containing regimens were preferred as initial treatment; they were used in 147 patients (51.8%). In total, 80% of patients were treated with one or more novel agents (thalidomide, lenalidomide, or bortezomib). Among 228 patients who were treated with novel agents as an initial treatment, the overall response rate (partial response (PR) or better) to initial treatment was 78.4%, and the median time to next treatment (TTNT) was 11.6 months. In the multivariate analysis, PR or better responses to initial treatment were independently favorable prognostic factors for TTNT. The median survival time after initial therapy for patients with novel agents was 56.4 months and 3-year overall survival (OS) was 70.4%. In multivariate analysis, ISS stage I/II disease and PR or better response to initial treatment, and autologous stem cell transplantation (ASCT) were identified as independent prognostic factors for overall survival (OS). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results